Back

Deep learning-based identification of necrosis and microvascular proliferation in adult diffuse gliomas from whole-slide images

Guo, Y.; Huang, H.; Liu, X.; Zou, W.; Qiu, F.; Liu, Y.; Chai, R.; Jiang, T.; Wang, J.

2025-08-16 pathology
10.1101/2025.08.14.25333656 medRxiv
Show abstract

For adult diffuse gliomas (ADGs), most grading can be achieved through molecular subtyping, retaining only two key histopathological features for high-grade glioma (HGG): necrosis (NEC) and microvascular proliferation (MVP). We developed a deep learning (DL) framework to automatically identify and characterize these features. We trained patch-level models to detect and quantify NEC and MVP using a dataset that employed active learning, incorporating patches from 621 whole-slide images (WSIs) from the Chinese Glioma Genome Atlas (CGGA). Utilizing trained patch-level models, we effectively integrated the predicted outcomes and positions of individual patches within WSIs from The Cancer Genome Atlas (TCGA) cohort to form datasets. Subsequently, we introduced a patient-level model, named PLNet (Probability Localization Network), which was trained on these datasets to facilitate patient diagnosis. We also explored the subtypes of NEC and MVP based on the features extracted from patch-level models with clustering process applied on all positive patches. The patient-level models demonstrated exceptional performance, achieving an AUC of 0.9968, 0.9995 and AUPRC of 0.9788, 0.9860 for NEC and MVP, respectively. Compared to pathological reports, our patient-level models achieved the accuracy of 88.05% for NEC and 90.20% for MVP, along with a sensitivity of 73.68% and 77%. When sensitivity was set at 80%, the accuracy for NEC reached 79.28% and for MVP reached 77.55%. DL models enabled more efficient and accurate histopathological image analysis which will aid traditional glioma diagnosis. Clustering-based analyses utilizing features extracted from patch-level models could further investigate the subtypes of NEC and MVP.

Matching journals

The top 7 journals account for 50% of the predicted probability mass.

1
Neuro-Oncology Advances
25 papers in training set
Top 0.1%
13.2%
2
Science Bulletin
21 papers in training set
Top 0.1%
10.0%
3
Nature Communications
5641 papers in training set
Top 22%
7.4%
4
Communications Medicine
113 papers in training set
Top 0.3%
6.4%
5
Cell Discovery
57 papers in training set
Top 0.1%
5.6%
6
Nature Machine Intelligence
70 papers in training set
Top 0.5%
4.9%
7
Scientific Reports
3612 papers in training set
Top 19%
4.9%
50% of probability mass above
8
PLOS ONE
5266 papers in training set
Top 34%
4.1%
9
Journal of Pathology Informatics
15 papers in training set
Top 0.1%
2.8%
10
Advanced Science
286 papers in training set
Top 4%
2.2%
11
npj Precision Oncology
53 papers in training set
Top 0.6%
2.2%
12
National Science Review
21 papers in training set
Top 0.1%
1.8%
13
Medical Image Analysis
35 papers in training set
Top 0.4%
1.8%
14
Modern Pathology
22 papers in training set
Top 0.2%
1.5%
15
npj Digital Medicine
118 papers in training set
Top 2%
1.5%
16
IEEE Journal of Biomedical and Health Informatics
37 papers in training set
Top 0.7%
1.5%
17
iScience
1154 papers in training set
Top 21%
1.5%
18
BMC Cancer
67 papers in training set
Top 1%
1.5%
19
PLOS Computational Biology
1863 papers in training set
Top 16%
1.4%
20
Clinical Cancer Research
64 papers in training set
Top 1%
1.2%
21
eLife
5828 papers in training set
Top 60%
1.0%
22
Biology Methods and Protocols
61 papers in training set
Top 2%
0.9%
23
IEEE/ACM Transactions on Computational Biology and Bioinformatics
38 papers in training set
Top 1%
0.6%
24
Cancer Research
130 papers in training set
Top 3%
0.6%
25
The Lancet Digital Health
25 papers in training set
Top 0.8%
0.6%
26
Theranostics
37 papers in training set
Top 1%
0.6%
27
eBioMedicine
183 papers in training set
Top 7%
0.6%
28
BMC Bioinformatics
457 papers in training set
Top 6%
0.6%
29
Journal of Cheminformatics
29 papers in training set
Top 0.8%
0.6%
30
Communications Biology
993 papers in training set
Top 33%
0.6%